OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Biachi on the Growing Treatment Landscape in HCC

September 27th 2023

Tiago Biachi, MD, PhD, discusses the growing treatment landscape for patients with hepatocellular carcinoma.

Dr Mastroyannis on the Administration and Utility of HIPEC in Ovarian Cancer

September 27th 2023

S. Alex Mastroyannis, MD, MSCE, discusses the administration and role of hyperthermic intraperitoneal chemotherapy in ovarian cancer, as well as its benefit for patients in the phase 3 OVHIPEC-1 trial.

Dr Zarrabi on Questions Regarding the Use of Triplet Therapy in Prostate Cancer

September 27th 2023

Kevin Kayvan Zarrabi, MD, MS, FACP, discusses remaining questions regarding treatment consisting of triplet therapy in patients with metastatic castration-sensitive prostate cancer.

Dr Kulasinghe on a Study Profiling the NSCLC Tumor Microenvironment

September 27th 2023

Arutha Kulasinghe, PhD, discusses findings from a study profiling the tumor microenvironment of non–small cell lung cancer, as well as future directions planned with this research and the implications of these findings.

Dr Billè on the Use of Minimally Invasive Surgery vs Stereotactic Radiotherapy in NSCLC

September 27th 2023

Andrea Billè, MD, discusses findings from a propensity-matched comparison of minimally invasive surgery vs stereotactic ablative radiotherapy in patients with clinical stage I non–small cell lung cancer.

Dr. Zhang on the Selection of Immunotherapy-Based Regimens in Metastatic RCC

September 27th 2023

Tian Zhang, MD, MHS, discusses the selection of first-line immunotherapy-based treatments for patients with metastatic renal cell carcinoma.

Dr Narayan on Variations in Breast Cancer Outcomes by Race

September 26th 2023

Anand Narayan, MD, PhD, discusses how outcomes differ between different subgroups of patients who are diagnosed with breast cancer, highlighting how these differences tie back to disparities in cancer care.

Dr Hecht on Barriers to Enrollment into the BASECAMP-1 Study in Solid Tumors

September 26th 2023

J. Randolph (Randy) Hecht, MD, discusses barriers to enrollment in the observational BASECAMP-1 study and the phase 1/2 EVEREST-1 study, which will investigate HLA-A*02 as a target for the novel CAR T-cell therapy A2B530 in patients with solid tumors.

Dr Qin on the Use of CAR T-Cell Therapy in ccRCC

September 26th 2023

Qian (Janie) Qin, MD, discusses the investigation and use of CAR T-cell therapy in patients with advanced clear cell renal cell carcinoma.

Dr Margulis on Key Considerations When Navigating Frontline Combination Regimens in RCC

September 26th 2023

Vitaly Margulis, MD, discusses key disease characteristics and patient factors to consider when selecting between IO/IO vs IO/TKI treatment combinations for the management of patients with renal cell carcinoma.

Dr. Disis on the Rationale For Investigating PRGN-3005 With/Without Lymphodepletion in Ovarian Cancer

September 26th 2023

Mary “Nora” Disis, MD, discusses the rationale for investigating the efficacy and optimal delivery of PRGN-3005 autologous UltraCAR T cells in patients with advanced stage platinum-resistant ovarian cancer.

Dr Hecht on the Investigation of the Novel CAR T-Cell Therapy A2B530 in Solid Tumors

September 25th 2023

J. Randolph (Randy) Hecht, MD, discusses the observational BASECAMP-1 study and the investigation of HLA-A*02 as a target for the novel CAR T-cell therapy A2B530 in the phase 1/2 EVEREST-1 study, which will investigate A2B530 in patients with solid tumors.

Dr Qin on Emerging Treatment Options in ccRCC

September 25th 2023

Qian (Janie) Qin, MD, discusses emerging treatment regimens for patients with advanced clear cell renal cell carcinoma.

Dr Chari on the Safety Profile of Talquetamab in Relapsed/Refractory Multiple Myeloma

September 25th 2023

Ajai Chari, MD, director, discusses the safety profile of talquetamab following the drug’s FDA approval for patients with relapsed/refractory multiple myeloma.

Dr Riess on the Initial Efficacy of the IO102-IO103 Vaccine Plus Pembrolizumab in Lung Adenocarcinoma

September 25th 2023

Jonathan W. Riess, MD, MS, discusses preliminary results from a phase 2 trial of the IO102-IO103 immuno-modulating cancer vaccine plus pembrolizumab in patients with metastatic non–small cell lung cancer adenocarcinoma.

Dr Aerts on Results From the DENIM Trial of Dendritic Cell Vaccination in Mesothelioma

September 25th 2023

Joachim G. J. V. Aerts, MD, PhD, discusses findings from the phase 3 DENIM trial in patients with mesothelioma, which was presented at the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer.

Experts Highlight Their Biggest Takeaways from the 2023 SOHO Annual Meeting

September 25th 2023

Key opinion leaders from across the hematologic oncology realm shared their biggest takeaways from the 2023 SOHO Annual Meeting.

Dr Daver on the Investigation of Uproleselan Plus Azacitidine and Venetoclax in AML

September 22nd 2023

Naval G. Daver, MD, discusses the rationale for an ongoing phase 1 trial investigating uproleselan in combination with azacitidine and venetoclax in patients with treatment-naïve acute myeloid leukemia.

Dr Jänne on Trastuzumab Deruxtecan in HER2-Mutant NSCLC

September 22nd 2023

Pasi A. Jänne, MD, PhD, discusses key findings from the primary analysis of the phase 2 DESTINY-Lung02 trial in patients with HER2-mutant non–small cell lung cancer.

Dr Pothuri on the Use of ADCs in Ovarian Cancer

September 22nd 2023

Bhavana Pothuri, MD, discusses the use of antibody-drug conjugates in patients with ovarian cancer and AEs to be aware of when treating patients with these therapies.